Title

PND109 Improvements in Patient-Reported Migraine PAIN Intensity and Composite Migraine Symptoms with Fremanezumab in the Real World

Document Type

Conference Proceeding

Publication Date

12-2020

Publication Title

Value in Health

Abstract

Objectives: Fremanezumab, a fully-humanized monoclonal antibody (IgG2Δa) that selectively targets the calcitonin gene-related peptide (CGRP) pathway, has been approved for migraine prevention in adults with episodic migraine (EM) or chronic migraine (CM). However, little data exists on the effectiveness of fremanezumab in a real-world setting. This retrospective, observational cohort study assessed real-world patient-reported changes in migraine pain intensity (MPI) and composite migraine symptoms (headache frequency/symptoms) after starting fremanezumab therapy. Methods: Data were extracted from September 2018 through June 2020 from the Midwest component of EMRClaims+®, an integrated health services database containing >20 million medical records from national commercial insurance claims, Medicare claims, and regional electronic medical records. Patients included were aged ≥18 years and were administered fremanezumab, with enrollment or treatment history ≥6 months prior to initiating fremanezumab (index date) and enrollment or treatment encounter ≥1 month after the index date. MPI (10-point visual analog scale [VAS; 0=no pain, 10=worst pain]) and patient-reported change in headache frequency/symptoms were assessed pre-index and ≥1 month after fremanezumab initiation. Wilcoxon signed-rank tests were used to compare MPI and headache frequency/symptoms before and after fremanezumab initiation. Results: Seventy-four patients (EM, n=21; CM, n=49) were eligible for analysis of MPI. MPI decreased significantly by 18% after fremanezumab initiation in the overall population: mean (standard deviation [SD]) VAS pain score was 5.47 (3.19) pre-index versus 4.51 (3.34) post-index (P=0.014). After fremanezumab initiation, pain levels decreased significantly by 45% in patients with EM (mean [SD] VAS pain score: pre-index, 5.57 [3.56]; post-index, 3.04 [3.37]; P=0.002) and decreased non-significantly by 10% in patients with CM after fremanezumab initiation (pre-index, 5.61 [2.99]; post-index, 5.06 [3.16]; P=0.203). Among patients who self-reported changes in headache frequency/symptoms (n=129), 83.7% reported improvement after fremanezumab initiation. Conclusions: After fremanezumab initiation, MPI decreased significantly and the majority of patients reported an improvement in headache frequency/symptoms.

Volume

23

Issue

Suppl 2

First Page

S642

This document is currently not available here.

Share

COinS